|
gptkbp:instanceOf
|
gptkb:drug
opioid receptor agonist
|
|
gptkbp:abusePotential
|
high (at very high doses)
low (at recommended doses)
|
|
gptkbp:ATCCode
|
A07DA03
|
|
gptkbp:brand
|
gptkb:Imodium
|
|
gptkbp:CASNumber
|
53179-11-6
|
|
gptkbp:chemicalFormula
|
C29H33ClN2O2
piperidine derivative
|
|
gptkbp:contraindication
|
gptkb:pseudomembranous_colitis
children under 2 years
bacterial enterocolitis
bloody diarrhea
|
|
gptkbp:discoveredBy
|
gptkb:Paul_Janssen
|
|
gptkbp:discoveredIn
|
1969
|
|
gptkbp:doesNotCross
|
blood-brain barrier (in normal doses)
|
|
gptkbp:drugClass
|
antidiarrheal
peripherally acting opioid
|
|
gptkbp:eliminationHalfLife
|
9-14 hours
|
|
gptkbp:excretion
|
feces
urine (minor)
|
|
gptkbp:FDAApproved
|
1976
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
loperamide
|
|
gptkbp:interactsWith
|
gptkb:desmopressin
gptkb:ritonavir
gptkb:gemfibrozil
gptkb:erythromycin
gptkb:ketoconazole
gptkb:verapamil
quinidine
|
|
gptkbp:lactationSafety
|
caution advised
|
|
gptkbp:legalStatus
|
OTC (over-the-counter) in many countries
Rx-only in some countries
|
|
gptkbp:marketedAs
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist in the gut
|
|
gptkbp:MedlinePlusID
|
a682280
|
|
gptkbp:metabolism
|
gptkb:CYP2C8
gptkb:CYP3A4
liver
|
|
gptkbp:molecularWeight
|
477.04 g/mol
|
|
gptkbp:overdoseSymptoms
|
gptkb:arrhythmia
QT prolongation
CNS depression (at very high doses)
|
|
gptkbp:patent
|
1972
|
|
gptkbp:pregnancyCategory
|
gptkb:B3
B (US)
|
|
gptkbp:PubChem_CID
|
3955
DB00836
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
constipation
drowsiness
|
|
gptkbp:UNII
|
6X9OC3H4II
|
|
gptkbp:usedFor
|
diarrhea
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Imodium
|
|
gptkbp:bfsLayer
|
5
|